Clinical

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Durvalumab plus BCG also marks the first new treatment in more than 30 years for high-risk non–muscle-invasive bladder cancer.

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed or refractory multiple myeloma, offering hope when IMiDs stop working.

Week 96 SOLSTICE data show tobevibart plus elebsiran deepens durable hepatitis D virus (HDV) and HBsAg suppression, beating monotherapy.

Elliot Tapper, MD, explains how digital health, precise screening, and direct hepatology care can treat alcohol-associated liver disease and mental health.

Re-engagement rates for patients with hepatitis B lost to follow-up range from 2% to 100% globally, with proximity to patients driving the best outcomes.

A population study finds familial melanoma gene variants are more common than thought, linking them to a higher risk of multiple cancers beyond melanoma.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

Seventy percent of participants rated total symptom clearance as very important—higher than any other treatment attribute, including speed of response or convenience. How does this align with what dermatologists have traditionally defined as treatment success?

ACS updated CRC screening guidelines, adding blood-based and stool tests to expand screening access and improve early detection.

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

A study led by Meng-Han Tsai, PhD, found that men and racial and ethnic minority patients with early-onset CRC in urban areas face a higher CVD death risk.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.

Rising urine albumin signals higher heart and kidney risk; learn how better screening, EHR prompts, and new therapies can transform CKD care.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

Discover the stroke care team—from primary care to rehab—plus proven prevention steps and the high stakes of recurrent stroke.

Stroke subtypes vary widely, but prevention is clear: control blood pressure, diabetes, cholesterol, exercise, quit smoking, and cut disability costs.

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about rural disparities.

James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).

Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.